, Tracking Stock Market Picks
Enter Symbol:
Allos Therapeutics, Inc. (ALTH) [hlAlert]

down 71.99 %

Allos Therapeutics, Inc. (ALTH) rated Buy with price target $11 by Citigroup

Posted on: Thursday,  Jun 26, 2008  8:25 AM ET by Citigroup

Citigroup rated Buy Allos Therapeutics, Inc. (NASDAQ: ALTH) on 06/26/2008, when the stock price was $6.57. Since
then, Allos Therapeutics, Inc. has lost 71.99% as of 09/05/2012's recent price of $1.84.
If you would have followed this Citigroup's recommendation on ALTH, you would have lost 71.99% of your investment in 1532 days.

Allos Therapeutics is a pharmaceutical company focused on developing andcommercializing innovative small molecule drugs, initially for improving cancer treatments. The company's lead product candidate is RSR13. RSR13 is a synthetic small molecule that increases the release of oxygen from hemoglobin, the oxygen-carrying protein contained within red blood cells.

Citi Investment Research is a highly respected research unit and is comprised of 390 research analysts across 22 countries. Citi Investment Research covers 3,100 companies, representing 90 percent of the market capitalization of the major global indices, and provides macro and quantitative analysis of global markets and sector trends. Combined with Citi's exceptional sales and trading capabilities and Smith Barney's financial consultants, the core focus of the group is to help investing clients make informed decisions by providing value-added, independent, insightful analysis.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/26/2008 8:25 AM Buy
6.57 11.00
as of 12/24/2008
1 Week down  -1.37 %
1 Month down  -11.94 %
3 Months down  -19.46 %
1 YTD down  -6.04 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy